Gregory Yanik, MD

Over the past three decades, allogeneic stem cell transplants (SCTs) have emerged as an important treatment for a number of malignant and nonmalignant disorders. Unfortunately, several complications, including graft-versus-host disease (GVHD) and pulmonary dysfunction, limit the utility of this form of therapy.